Instead Launches Tax Reports – Maximizing Savings for Individuals and Businesses
SAN FRANCISCO, June 09, 2025 (GLOBE NEWSWIRE) -- Instead, a pioneering tax management platform, today announces the official launch of its game-changing AI-driven tax reports, designed to transform how business owners and individuals make tax decisions and maximize tax savings.
Instead's platform empowers users to get ahead of tax deadlines by transforming reactive filing into proactive financial strategy. By harnessing artificial intelligence to analyze every line of the tax return, users uncover eligible tax strategies and missed opportunities.
Reports include:
Tax Return Analysis Report – Reveals tax-saving opportunities in tax returns for individuals (1040) and businesses (Schedule C, E, F, 1120, 1120S, 1065).
Tax Plan Report – Provides a real-time summary and action list of all tax strategies across all entities in a tax year. This includes potential and actual savings, summaries for each tax strategy, and IRS and court case references.
Tax Strategy Reports – One for every tax strategy, complete with detailed calculations of deductions and credits, supporting documentation, and an actionable plan including common pitfalls and steps to file.
Every report is designed for clarity, compliance, and confidence and is backed by detailed calculations and real-time updates to support your final tax return.
Instead users can invite their tax professional to collaborate on tax strategies or search the directory of firms who support the Instead platform and offer tax planning and advisory. All tools are built to ensure users and their advisors can maximize tax savings together with transparency and ease.
'We are excited to bring our users the future of smart, effective decisions when it comes to filing taxes,' states Andrew Argue, CPA and CEO and co-founder of Instead. 'With Instead, users can easily uncover and implement tax strategies and opportunities that will save them money and have the transparent calculations to support a tax return. And this is just the beginning…we have some exciting things on our roadmap and look forward to sharing them very soon!'
A free trial is available. For more information or to sign up, visit www.instead.com.
About InsteadInstead (www.instead.com) is revolutionizing tax management as the first company in decades to receive IRS and state approvals to file individual, business, trust and estate returns. The platform uses AI to analyze tax returns, identify missed opportunities, and implement tax-saving strategies with supporting documentation. Starting at $16/month, Instead helps individuals, businesses, and tax professionals save tens to hundreds of thousands on taxes through intelligent tax analysis rather than last-minute filing.
Media ContactVicki LaBrosseEdge Marketing for InsteadVlabrosse@edgemarketinginc.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hamilton Spectator
an hour ago
- Hamilton Spectator
MediPharm Reminds Shareholders to Vote in Advance of June 13 Deadline
TORONTO, June 11, 2025 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ('MediPharm,' the 'Company,' 'we' or 'us'), a pharmaceutical company specialized in precision-based cannabinoids, today reminded its shareholders that the deadline is approaching to cast your vote for the upcoming Annual and Special Meeting of Shareholders on June 16, 2025 (the 'Meeting'). All votes must be received no later than 3:00 p.m. (Eastern time) on Friday, June 13, 2025. We encourage shareholders to please vote using ONLY the GREEN proxy or GREEN voting instruction card and to support each of the director nominees recommended by MediPharm's Board of Directors (the 'Board') and the other matters being considered at the Meeting. To ensure your proxy is counted at the Meeting, please submit it well in advance of the June 13 proxy cut-off. Please remember that your vote is important, regardless of the number of shares you own. MediPharm's Strategy Is Working MediPharm has undergone a successful transformation over the past three years, led by David Pidduck who joined as CEO in April 2022. Faced with negative gross margins and an operating loss of $48.9 million in 2021, the Company implemented a plan to refocus operations, prioritizing the most strategic business lines, divesting of non-core assets and reducing operating costs. The acquisition of VIVO Cannabis Inc. in April 2023 provided a foundation to accelerate international growth and realize synergies from combining the two companies. We described our strategic turnaround in a Chair's Letter to Shareholders dated May 11, 2025 . In Q1 2025, we continued our track record of year-over-year revenue growth, led by an 87% revenue increase in the international medical market which now represents more than half our revenue. We achieved positive Adjusted EBITDA1 for the first time in more than five years and our gross profit margin of 38.7% was the highest in more than five years. Operating loss narrowed to less than $0.5 million, an improvement of more than $3 million from Q1 2024. A strong cash position with virtually no debt enabled us to invest in inventory to pursue near-term growth opportunities. With diversification in our product mix and sales channels, a strong reputation as a GMP-certified producer and expanding international partnerships, MediPharm has established a solid foundation for further growth. We are confident the strategy and team currently in place is the best way to create sustainable value. The Dissident Group has NOT Made a Case for Change Apollo Technology Capital Corp. ('Apollo'), led by Chairman and CEO Regan McGee, and former MediPharm CEO and director Patrick McCutcheon (collectively, the 'Concerned Stakeholder'), have filed an amended and restated dissident proxy circular dated May 15, 2025, as updated by an addendum dated June 4, 2025, nominating six alternative directors (the 'Dissident Nominees') for the Board. In recent weeks we have described numerous deficiencies in Apollo's plan and the track record of Mr. McGee and the other Dissident Nominees. With the addition of Pat McCutcheon to the dissident team, a number of new concerns now emerge. Important points for shareholders to remember include the following. Patrick McCutcheon's Tenure at MediPharm Mr. McCutcheon, who is now formally acknowledged as a member of the Concerned Stakeholder dissident group, served as CEO of MediPharm until December 10, 2020, Chairman of the Board until August 16, 2021, and as a director until December 7, 2021. While Apollo has been critical of the current leadership team's performance on such measures as share price, revenue growth, gross profit, cash usage and operating loss, we note the following about Mr. McCutcheon's track record with the Company. The Board urges shareholders to send Mr. McGee and Mr. McCutcheon a strong message that you want to stop their expensive and aggressive attacks against your Company. Vote for the Highly Qualified MediPharm Nominees MediPharm urges shareholders to vote only using the GREEN proxy or GREEN voting instruction form in support of all of the Company's nominees and resolutions. To ensure your vote is counted, shareholders are encouraged to proactively contact their broker to obtain their 16-digit control number associated with the GREEN management proxy. Once received, you can cast your vote by visiting . You may receive materials or outreach from the dissident — please disregard any such communications and vote only using the GREEN proxy in support of the Company's nominees. About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA. In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. Shareholder Voting Assistance: If you have any questions or require any assistance in executing your GREEN proxy or voting instruction form, please call Sodali & Co at: North American Toll-Free Number: 1.888.777.2059 Outside North America, Banks, Brokers and Collect Calls: 1.289.695.3075 Email: assistance@ North American Toll-Free Facsimile: 1.877.218.5372 For up-to-date information and assistance in voting please visit: Investor Contact: MediPharm Labs Investor Relations Telephone: +1 416.913.7425 Email: investors@ Media Contact: John Vincic Oakstrom Advisors +1 (647) 402-6375 john@ Cautionary Note Regarding Forward-Looking Information: This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things: timing of the Annual and Special Meeting, the ability of the Company to pursue near-term growth opportunities, future growth opportunities available to the Company, sustainable value creation at MediPharm, any impacts to MediPharm shareholders of the actions relating to the Dissident Nominees described herein, and any outcomes resulting from the circumstances and information cited herein. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs' continuous disclosure filings, available on the SEDAR+ website at . There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change. ___________________________________ 1 Represents a non-GAAP financial measure, which is not a standardized financial measure under IFRS and which might not be comparable to similar financial measures disclosed by other issuers. MediPharm calculates Adjusted EBITDA as net income (loss) with interest, taxes, depreciation and amortization, non-cash adjustments and other unusual or non-recurring items added back. Refer to the sections entitled 'Use of Non-IFRS Financial Measures' and 'Reconciliation of Non-IFRS Measures' in MediPharm's management's discussion and analysis for the three months ended March 31, 2025, which is incorporated by reference herein and which can be located on MediPharm's profile on SEDAR+ at .
Yahoo
an hour ago
- Yahoo
EHP Inc. Launches National Affiliate Expansion Initiative to Accelerate Employer Healthcare Innovation Under Mardy Gould's Leadership
Jacksonville, FL, June 11, 2025 (GLOBE NEWSWIRE) -- EHP Inc., a leading provider of compliant, tax-efficient employee benefit programs, announced the launch of its 2025 National Affiliate Expansion Initiative, a strategic move aimed at scaling its transformative employer-focused healthcare model across the U.S. The initiative is spearheaded by Co-Founder and Managing Partner Mardy Gould, reaffirming the company's commitment to innovation, compliance, and growth through a robust partner ecosystem. Mardy Gould This newly launched initiative marks a pivotal step in EHP Inc.'s nationwide growth strategy, offering new opportunities for professionals and non-traditional partners to join the company's thriving affiliate network. With over 10,000 affiliates already active, the expansion initiative will provide additional training, real-time tools, and access to EHP's proprietary AI-powered compliance infrastructure, enabling partners to deliver the company's tax-smart, employee-first benefits model with confidence and scale. A Timely Expansion Driven by Founder-Led Vision The launch of the Affiliate Expansion Initiative comes amid increasing demand from mid-sized and large employers seeking effective ways to lower healthcare costs and improve employee engagement without overhauling their existing insurance. EHP Inc.'s structure, based on IRS Sections 125, 105, and 213(d), allows employers to reduce their FICA tax burden by $650 to $750 per employee annually while enhancing preventive healthcare access. 'This expansion initiative reflects our belief that smart growth starts with strong partners,' said Mardy Gould. 'We built EHP Inc. on the principles of compliance, transparency, and impact — and we're inviting professionals across the country to be part of a proven model that actually helps employers solve real problems.' The Employer's Choice for Modern, Tax-Advantaged Healthcare EHP Inc. stands out by offering a fully IRS-compliant model that integrates seamlessly with existing payroll systems and insurance plans. The program requires no out-of-pocket costs from employers and offers employees a suite of wellness services, including virtual primary care, care navigation, and personalized advocacy, services that are delivered in addition to any current benefits. Legal and ERISA-reviewed, the EHP structure helps employers retain talent, improve health outcomes, and achieve cost-efficiency without introducing unnecessary complexity. What Makes the 2025 Expansion Initiative Newsworthy The launch of this initiative represents a major milestone for EHP Inc. It includes: Regional Training Sessions: A calendar of in-person and virtual affiliate training sessions scheduled across major U.S. cities beginning July 2025. Enhanced Partner Tools: Access to a newly updated Affiliate Portal, with AI-powered proposal generation, real-time commission tracking, and automated compliance updates. Tiered Compensation Model: A refined affiliate earnings structure designed to accelerate success for both new and experienced partners. Turnkey Onboarding: Streamlined onboarding powered by smart automation, ensuring that affiliates can activate quickly and compliantly. These enhancements are expected to double the company's affiliate footprint by year's end and strengthen its position as The Employer's Choice in employer-driven healthcare benefits. AI-Driven Compliance and National Infrastructure Central to the success of EHP Inc.'s model is its proprietary compliance automation platform, which governs everything from onboarding and documentation to payroll analysis and partner communications. The platform uses AI to maintain IRS and ERISA compliance while minimizing administrative burden for both employers and affiliates. 'Our infrastructure isn't just scalable; it's protective,' said Gould. 'Every piece of our system is designed to safeguard our clients, our partners, and our mission.' Leadership Continuity Fuels Nationwide Momentum Unlike many rapidly growing companies, EHP Inc. remains founder-led, with its original leadership team still driving strategic direction. Mardy Gould continues to play an active role in expanding partnerships, shaping program design, and advocating for smarter employer benefits at industry forums nationwide. 'We've never lost sight of why we started EHP,' Gould added. 'Our mission was, and still is, to give employers better choices through compliant, tax-savvy solutions. This affiliate expansion is a natural extension of that promise.' About EHP Inc. Headquartered in Jacksonville, Florida, EHP Inc. is a national employer solutions provider offering tax-advantaged, IRS-compliant benefit programs under IRS Sections 125, 105, and 213(d). The company helps businesses lower payroll tax liability and redirect those savings toward meaningful, preventive care for employees. With a strong legal foundation, AI-driven compliance, and a growing network of affiliates, EHP Inc. is redefining how companies manage cost, care, and compliance. To learn more about the 2025 National Affiliate Expansion Initiative or to become an affiliate, visit EHP The Employer's ChoiceCONTACT: Media Contact: Company Name: EHP Inc. Contact Person: Alex Barret Email: info@ Phone: 904-257-6217 Country: United States Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
MediPharm Reminds Shareholders to Vote in Advance of June 13 Deadline
Shareholders Urged to Vote for Proven Strategy and Team, Reject Dissident's Inadequate Plan and Nominees TORONTO, June 11, 2025 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ('MediPharm,' the 'Company,' 'we' or 'us'), a pharmaceutical company specialized in precision-based cannabinoids, today reminded its shareholders that the deadline is approaching to cast your vote for the upcoming Annual and Special Meeting of Shareholders on June 16, 2025 (the 'Meeting'). All votes must be received no later than 3:00 p.m. (Eastern time) on Friday, June 13, 2025. We encourage shareholders to please vote using ONLY the GREEN proxy or GREEN voting instruction card and to support each of the director nominees recommended by MediPharm's Board of Directors (the 'Board') and the other matters being considered at the Meeting. To ensure your proxy is counted at the Meeting, please submit it well in advance of the June 13 proxy cut-off. Please remember that your vote is important, regardless of the number of shares you own. MediPharm's Strategy Is Working MediPharm has undergone a successful transformation over the past three years, led by David Pidduck who joined as CEO in April 2022. Faced with negative gross margins and an operating loss of $48.9 million in 2021, the Company implemented a plan to refocus operations, prioritizing the most strategic business lines, divesting of non-core assets and reducing operating costs. The acquisition of VIVO Cannabis Inc. in April 2023 provided a foundation to accelerate international growth and realize synergies from combining the two companies. We described our strategic turnaround in a Chair's Letter to Shareholders dated May 11, 2025. In Q1 2025, we continued our track record of year-over-year revenue growth, led by an 87% revenue increase in the international medical market which now represents more than half our revenue. We achieved positive Adjusted EBITDA1 for the first time in more than five years and our gross profit margin of 38.7% was the highest in more than five years. Operating loss narrowed to less than $0.5 million, an improvement of more than $3 million from Q1 2024. A strong cash position with virtually no debt enabled us to invest in inventory to pursue near-term growth opportunities. With diversification in our product mix and sales channels, a strong reputation as a GMP-certified producer and expanding international partnerships, MediPharm has established a solid foundation for further growth. We are confident the strategy and team currently in place is the best way to create sustainable value. The Dissident Group has NOT Made a Case for Change Apollo Technology Capital Corp. ('Apollo'), led by Chairman and CEO Regan McGee, and former MediPharm CEO and director Patrick McCutcheon (collectively, the 'Concerned Stakeholder'), have filed an amended and restated dissident proxy circular dated May 15, 2025, as updated by an addendum dated June 4, 2025, nominating six alternative directors (the 'Dissident Nominees') for the Board. In recent weeks we have described numerous deficiencies in Apollo's plan and the track record of Mr. McGee and the other Dissident Nominees. With the addition of Pat McCutcheon to the dissident team, a number of new concerns now emerge. Important points for shareholders to remember include the following. Apollo's strategic plan for MediPharm appears to have been hastily constructed and lacking in substance, while presenting current MediPharm strategies as their own. Apollo has shown inconsistencies regarding support for or aversion to M&A activities. We provided a detailed analysis of Apollo's inadequate plan in our Board Letter to Shareholders issued May 29, 2025. Apollo's disclosure has been characterized by numerous misrepresentations and outright fabrications. We highlighted a small sample of the false statements they have made in an 'Apollo Myths vs. Facts' document on our AGM website. Independent proxy voting and corporate governance advisory firm ISS met with Apollo, considered its arguments and its plans for the Company and concluded that Apollo did not make a compelling case for change. Please see our news release issued June 2, 2025 for more details. The Dissident Nominees have potential conflicts of interest and a web of interlocking relationships that would impair their independence as Board members. We described these problems in our May 15, 2025 news release. Patrick McCutcheon's Tenure at MediPharm Mr. McCutcheon, who is now formally acknowledged as a member of the Concerned Stakeholder dissident group, served as CEO of MediPharm until December 10, 2020, Chairman of the Board until August 16, 2021, and as a director until December 7, 2021. While Apollo has been critical of the current leadership team's performance on such measures as share price, revenue growth, gross profit, cash usage and operating loss, we note the following about Mr. McCutcheon's track record with the Company. One of Apollo's primary arguments has been that the current MediPharm team has been responsible for the decrease in the Company's share price since its peak on May 14, 2019. Of the total decrease in share price since May 14, 2019, more than 97% occurred while Mr. McCutcheon served as Chairman, CEO or director. Less than 1% of the total decrease has occurred since David Pidduck joined as CEO on April 20, 2022. In 2020, Mr. McCutcheon's final year as CEO, the Company's revenue decreased by 72% year-over-year with gross profit of negative $44.0 million, cash from operations of negative $37.8 million, and operating income of negative $72.6 million. We note Apollo's reference to the decrease in the Company's asset values over time. Some of this asset decrease was in fact due to the write-offs required as a result of Mr. McCutcheon's excessive multi-year capital expenditure program including the procurement of millions of dollars of equipment, much of which was not needed and was never used. The Board urges shareholders to send Mr. McGee and Mr. McCutcheon a strong message that you want to stop their expensive and aggressive attacks against your Company. Vote for the Highly Qualified MediPharm Nominees MediPharm urges shareholders to vote only using the GREEN proxy or GREEN voting instruction form in support of all of the Company's nominees and resolutions. To ensure your vote is counted, shareholders are encouraged to proactively contact their broker to obtain their 16-digit control number associated with the GREEN management proxy. Once received, you can cast your vote by visiting . You may receive materials or outreach from the dissident — please disregard any such communications and vote only using the GREEN proxy in support of the Company's nominees. About MediPharm Labs Founded in 2015, MediPharm Labs specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products utilizing a Good Manufacturing Practices certified facility with ISO standard-built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities for delivery of pure, trusted and precision-dosed cannabis products for its customers. MediPharm Labs develops, formulates, processes, packages and distributes cannabis and advanced cannabinoid-based products to domestic and international medical markets. In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic Good Manufacturing Practices License for the extraction of multiple natural cannabinoids. This GMP license was the first step in the Company's current foreign drug manufacturing site registration with the US FDA. In 2023, MediPharm acquired VIVO Cannabis Inc., which expanded MediPharm's reach to medical patients in Canada via Canna Farms medical ecommerce platform, and in Australia and Germany through Beacon Medical Australia PTY Ltd. and Beacon Medical Germany GMBH. This acquisition also included Harvest Medical Clinics in Canada which provides medical cannabis patients with Physician consultations for medical cannabis education and prescriptions. The Company carries out its operations in compliance with all applicable laws in the countries in which it operates. Shareholder Voting Assistance: If you have any questions or require any assistance in executing your GREEN proxy or voting instruction form, please call Sodali & Co at: North American Toll-Free Number: 1.888.777.2059Outside North America, Banks, Brokers and Collect Calls: 1.289.695.3075Email: assistance@ American Toll-Free Facsimile: 1.877.218.5372 For up-to-date information and assistance in voting please visit: Investor Contact: MediPharm Labs Investor RelationsTelephone: +1 416.913.7425Email: investors@ Media Contact: John VincicOakstrom Advisors+1 (647) 402-6375john@ Cautionary Note Regarding Forward-Looking Information: This news release contains 'forward-looking information' and 'forward-looking statements' (collectively, 'forward-looking statements') within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as 'expects', or 'does not expect', 'is expected', 'anticipates' or 'does not anticipate', 'plans', 'budget', 'scheduled', 'forecasts', 'estimates', 'believes' or 'intends' or variations of such words and phrases or stating that certain actions, events or results 'may' or 'could', 'would', 'might' or 'will' be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate to, among other things: timing of the Annual and Special Meeting, the ability of the Company to pursue near-term growth opportunities, future growth opportunities available to the Company, sustainable value creation at MediPharm, any impacts to MediPharm shareholders of the actions relating to the Dissident Nominees described herein, and any outcomes resulting from the circumstances and information cited herein. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; the inability of MediPharm Labs to obtain adequate financing; the delay or failure to receive regulatory approvals; and other factors discussed in MediPharm Labs' continuous disclosure filings, available on the SEDAR+ website at There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, MediPharm Labs assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change. ___________________________________ 1 Represents a non-GAAP financial measure, which is not a standardized financial measure under IFRS and which might not be comparable to similar financial measures disclosed by other issuers. MediPharm calculates Adjusted EBITDA as net income (loss) with interest, taxes, depreciation and amortization, non-cash adjustments and other unusual or non-recurring items added back. Refer to the sections entitled 'Use of Non-IFRS Financial Measures' and 'Reconciliation of Non-IFRS Measures' in MediPharm's management's discussion and analysis for the three months ended March 31, 2025, which is incorporated by reference herein and which can be located on MediPharm's profile on SEDAR+ at
